| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
* Department of Medicine,
Department of Pathology, and
Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095; and
Perlmutter Laboratory, Children’s Hospital and Harvard Medical School, Boston, MA 02118
Metastatic renal cell carcinoma (RCC) responds poorly to chemo- or radiation therapy but appears to respond to systemic immunotherapy (i.e., IL-2 and/or IFN-
), albeit with only 5–10% durable response. The CXCR3/CXCR3 ligand biological axis plays an important role in mediating type 1 cytokine-dependent cell-mediated immunity, which could be beneficial for attenuating RCC if optimized. We found that systemic IL-2 induced the expression of CXCR3 on circulating mononuclear cells but impaired the CXCR3 ligand chemotactic gradient from plasma to tumor by increasing circulating CXCR3 ligand levels in a murine model of RCC. Moreover, the antitumor effect of systemic IL-2 was CXCR3-dependent, as IL-2 failed to inhibit tumor growth and angiogenesis in CXCR3–/– mice. We hypothesized that the immunotherapeutic effect of the CXCR3/CXCR3 ligand biological axis could be optimized by first priming with systemic IL-2 to induce CXCR3 expression on circulating mononuclear cells followed by enhancing the intratumor CXCR3 ligand levels to establish optimal CXCR3-dependent chemotactic gradient. We found that combined systemic IL-2 with an intratumor CXCR3 ligand (CXCL9) lead to significantly greater reduction in tumor growth and angiogenesis, increased tumor necrosis, and increased intratumor infiltration of CXCR3+ mononuclear cells, as compared with either IL-2 or CXCL9 alone. The enhanced antitumor effect of the combined strategy was associated with a more optimized CXCR3-dependent chemotactic gradient and increased tumor-specific immune response. These data suggest that the combined strategy of systemic IL-2 with intratumor CXCR3 ligand is more efficacious than either strategy alone for reducing tumor-associated angiogenesis and augmenting tumor-associated immunity, the concept of immunoangiostasis.
This article has been cited by other articles:
|
|
 |
|
  M. Iguchi, M. Matsumoto, K. Hojo, T. Wada, Y. Matsuo, A. Arimura, and K. Abe Antitumor Efficacy of Recombinant Human Interleukin-2 Combined with Sorafenib Against Mouse Renal Cell Carcinoma Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 303 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Park, M. A. Hughes, M. Burdick, R. M. Strieter, and B. Mehrad Early NK Cell-Derived IFN-{gamma} Is Essential to Host Defense in Neutropenic Invasive Aspergillosis J. Immunol., April 1, 2009; 182(7): 4306 - 4312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Keeley, B. Mehrad, and R. M. Strieter Chemokines as Mediators of Neovascularization Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1928 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wendel, I. E. Galani, E. Suri-Payer, and A. Cerwenka Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-{gamma} and CXCR3 Ligands Cancer Res., October 15, 2008; 68(20): 8437 - 8445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Verzijl, S. Storelli, D. J. Scholten, L. Bosch, T. A. Reinhart, D. N. Streblow, C. P. Tensen, C. P. Fitzsimons, G. J. R. Zaman, J. E. Pease, et al. Noncompetitive Antagonism and Inverse Agonism as Mechanism of Action of Nonpeptidergic Antagonists at Primate and Rodent CXCR3 Chemokine Receptors J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 544 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-P. N Chow, C C Wu, H Y Chang, C Chang, and Y S Chang A simplified tumour model established via Epstein-Barr virus-encoded, nasopharyngeal carcinoma-derived oncogene latent membrane protein 1 in immunocompetent mice Lab Anim, April 1, 2008; 42(2): 193 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Klatte, D. B. Seligson, S. B. Riggs, J. T. Leppert, M. K. Berkman, M. D. Kleid, H. Yu, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma Clin. Cancer Res., December 15, 2007; 13(24): 7388 - 7393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Hwang, J. R. Lukens, and T. N. J. Bullock Cognate Memory CD4+ T Cells Generated with Dendritic Cell Priming Influence the Expansion, Trafficking, and Differentiation of Secondary CD8+ T Cells and Enhance Tumor Control J. Immunol., November 1, 2007; 179(9): 5829 - 5838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rotondi, L. Chiovato, S. Romagnani, M. Serio, and P. Romagnani Role of Chemokines in Endocrine Autoimmune Diseases Endocr. Rev., August 1, 2007; 28(5): 492 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Struyf, M. D. Burdick, E. Peeters, K. Van den Broeck, C. Dillen, P. Proost, J. Van Damme, and R. M. Strieter Platelet Factor-4 Variant Chemokine CXCL4L1 Inhibits Melanoma and Lung Carcinoma Growth and Metastasis by Preventing Angiogenesis Cancer Res., June 15, 2007; 67(12): 5940 - 5948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Dobrzanski, J. B. Reome, J. C. Hylind, and K. A. Rewers-Felkins CD8-Mediated Type 1 Antitumor Responses Selectively Modulate Endogenous Differentiated and Nondifferentiated T Cell Localization, Activation, and Function in Progressive Breast Cancer J. Immunol., December 1, 2006; 177(11): 8191 - 8201. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
